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Background Allocation of patients with hepatocellular carcinoma (HCC) to the adequate therapy is determined by both tumor
burden and liver function. The Barcelona Clinic Liver Cancer (BCLC) staging system and therapeutic algorithm recommends
transarterial chemoembolization (TACE) based on the best evidence available to patients with intermediate-stage HCC (BCLC-B).
However, many centers also treat subgroups of patients outside these recommendations and with more advanced disease by
TACE. The purpose of this study was to identify prognostic factors in a TACE cohort, including BCLC-B patients, as well as
patients treated outside of BCLC-B, to test the prognostic capabilities of published staging systems and to optimize
prognostication for TACE patients.
Patients and methods A cohort of 186 first-line TACE patients was analyzed. Independent prognostic factors were identified
and used to construct the Munich-TACE score (M-TACE). M-TACE was tested against established staging systems (including
BCLC and two recently published TACE-specific scores) and a ranking using concordance index and Akaike Information Criterion
was performed. Finally, an external validation in an independent TACE cohort (n=71) was conducted.
Results Bilirubin, Quick/international normalized ratio, C-reactive protein, creatinine, α-feto protein, and tumor extension were
identified as independent prognostic factors and used to construct M-TACE. M-TACE identifies three distinct subgroups
(P<0.0001) with median survival times of 35.2, 16.9, and 8.6 months, respectively. Compared with established staging systems,
M-TACE showed the best prognostic capabilities in both cohorts of patients (cohort 1: c-index, 0.71; Akaike Information
Criterion: 1276; cohort 2: c-index, 0.754).
Conclusion We identified independent risk factors for patients treated with TACE. The newly constructed M-TACE score is
superior to established staging systems and might prove helpful to identify patients who are most suitable for TACE.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most fre-
quent cancer entity worldwide. The course of the disease
often is complicated by underlying liver cirrhosis [1].
Transarterial chemoembolization (TACE) is an established
treatment method in the palliative setting with solid evi-
dence for improvement of survival [2]. However, con-
flicting data on the efficacy of TACE indicate that selecting
the right patients is a critical issue. HCC staging systems
taking into account both liver function and tumor para-
meters can be a valuable tool for treatment decisions. The
Barcelona Clinic Liver Cancer (BCLC) [3], the staging
system endorsed by the major liver associations [4,5], only
allocates patients in the intermediate stage B (asympto-
matic large or multinodular tumors without portal inva-
sion or extrahepatic spread, Child A-B) to TACE.
Conversely, in real-world clinical practice, this widely used
modality is not limited to stage B patients [6]. Recent
studies have demonstrated inferior prognostic abilities of
BCLC for TACE patients when compared with other sta-
ging systems [7]. As all established staging systems have
been developed in inhomogeneous HCC populations, it
remains unclear whether they consider the relevant prog-
nostic factors for TACE patients at all. In line with the call
for treatment-specific staging systems [8,9], two pre-
therapeutic TACE-specific scores have been proposed
recently [10,11]. A major aim of the current study was to
apply the available staging systems to a homogeneous
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TACE cohort and compare their prognostic quality. The
identification of prognostic factors should then be used to
create a new, potentially more accurate prognostic score
for patients evaluated for TACE; providing a tool for




In this retrospective study, we identified patients with
HCC between December 1999 and March 2011 (including
patients from a previous study [12]), who were treated
with conventional TACE at the University Hospital of
Munich (n= 234). The ethics committees of Munich and
Frankfurt (external cohort) had approved the study.
Patients who could not be classified in all staging systems
owing to missing clinical or radiological parameters were
excluded (n=21). Non-first-line TACE patients and those
receiving TACE as a mode of ‘bridging’ before liver
transplantation were excluded (n=27). The 186 patients
remaining formed the study population.
Data collection
Aiming at creating clinically practical tumor extension
criteria for TACE patients, the tumor extension criteria
defined by BCLC were modified: the term ‘portal invasion’
was replaced by ‘vascular involvement’ (defined by radio-
logical signs of direct tumor invasion of any hepatic vessel
or by portal vein thrombosis with or without signs of
direct tumor invasion); in addition, enlarged local lymph
nodes as a sign of extrahepatic disease were ignored, as
this parameter is considered an unspecific radiological
finding in the context of chronic liver disease. The external
cohort consisted of 71 TACE patients of the University
Hospital Frankfurt (2005–2012). Similar to the University
Hospital of Munich, this liver center has a longstanding
experience in HCC treatment including a liver transplant
program.
Tested staging systems
Five multidimensional [BCLC [3], Cancer-of-the-Liver-Italian-
Program (CLIP) [13], Groupe-d’Etude-et-de-Traitementdu-
Carcinome-Hepatocellulaire (GETCH) [14], Japan Integrated
Staging (JIS) [15], and Okuda [16]] and two unidimensional
scores (TNM [17] and Child–Pugh [18]) were tested. In
addition, two recently published TACE-specific scores were
applied: Selection for Transarterial Chemoembolization
Treatment (STATE) score [10] and Hepatoma Arterial
embolization Prognostic (HAP) score [11].
Transarterial chemoembolization
Indication for TACE was based upon interdisciplinary
discussion. In general, the TACE procedure was conducted
as follows: before each TACE (<4 weeks), a contrast-
enhanced computed tomography for intervention planning
purposes was performed. The TACE was carried out as
selectively as possible aiming at segmental or subsegmental
feeder arteries and dosage of the TACE components
(epirubicin, lipiodol, gelatin sponge) was adjusted to
tumor size, vascularization, and liver function. Sequential
TACE therapies were performed in patients without con-
traindications, if signs of tumor viability on follow-up
imaging persisted.
Statistical analysis
For statistical analysis, SAS software (SAS, version 9.2;
SAS Institute Inc., Cary, North Carolina, USA) was used.
P values less than 0.05 indicated statistical significance and
P values less than 0.0001 indicated high statistical
significance.
Univariate analysis
Overall survival (OS) was defined as time from the date of
first TACE until death or final follow-up. In univariate
analysis, OS was estimated by using the Kaplan–Meier
method. The log-rank test was used to compare the sur-
vival curves. In addition, the P-value medians of survival
time and 95% confidence intervals (95% CI) for the dif-
ferent strata are given. Both single parameters and the
whole scores were analyzed concerning their prognostic
significance. For Kaplan–Meier analysis of continuous
variables, one or more cutoff values are necessary; there-
fore, laboratory values were divided into quartiles.
Multivariate analysis and Munich-TACE construction
Those parameters with significance in univariate analysis
underwent multivariate testing by using the Cox propor-
tional hazards regression model. Creatinine and Quick were
categorized because Kaplan–Meier analysis of their quartiles
did not indicate linearity. All other laboratory values were
taken as base two logarithms and used as continuous vari-
ables. Clinical and tumor parameters were modified by
joining together those categories that lacked significant dis-
tinction in univariate analysis. As an example, the tumor
extension criteria were reduced from four to two categories
(category A: singular nodule<2 cm, three nodules≤3 cm,
one nodule≤5 cm; category B: large or multilocular, vascular
involvement, M1). The significant variables and interactions
between them were tested simultaneously and a model was
created using backward selection. Parameters with significant
prognostic meaning in multivariate analysis should serve as
the components of the new prognostic score. In order to keep
the score as simple as possible, a second, less complex Cox
model was calculated on the basis of the first one. For this,
final model interactions were ignored and continuous vari-
ables were categorized. Variables no longer significant in this
setting were excluded. Internal validation of the model was
performed by calculating the same model for 200 bootstrap
samples and determining the concordance index (c-index)
[19] for each sample. The mean value of these 200 c-indices
was used as an estimation, how good the new model would
be applicable to a new collective. In addition, for graphic
illustration, the cohort was split into tertiles by applying the
new model, and in the next step Kaplan–Meier curves for
the tertiles and the curves estimated from the Cox model
were plotted. For construction of the score, the specific
number of points for each category was estimated on the
basis of the coefficient of the Cox model. The final
arrangement of the Munich-TACE score (M-TACE) into its
stages was achieved by formation of tertiles.
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Ranking
Ranking of staging systems was conducted by using the
c-index [19] and the Akaike Information Criterion (AIC)
[20] derived from the Cox model. C-indices together with
95% CI were calculated using the SAS macro (SAS
Institute Inc.). As only the c-index is capable of directly
comparing the performance of a prognostic model in dif-




Baseline patient characteristics of the internal cohort are
shown in Table 1. The leading etiological factor was
alcohol abuse (45.7%) (Table S1, Supplemental digital
content 1, http://links.lww.com/EJGH/A236). The major-
ity of patients were male (80.6%), and the median age was
65.5 (range: 31.5–88.8) years. Liver cirrhosis was present
in 83.9%. Partial or total portal vein thrombosis was seen
in 11.8 and 1.6%. Liver function was compensated (no
cirrhosis or Child A) in 62.3%; only 9.1% had end-stage
liver disease (Child C). Almost all of the patients (97.9%)
were in a good or fairly good general condition [Eastern
Cooperative Oncology Group (ECOG) 0–1]. In all, 39.7%
showed more than three nodules. Vascular invasion and
distant metastasis were present in the minority of cases
(15.1 and 9.2%). The characteristics of the most relevant
baseline laboratory parameters are summarized in Table
S2 (Supplemental digital content 1, http://links.lww.com/
EJGH/A236). The median number of TACE interventions
was 3. The majority of patients received up to five (72.6%)
TACE interventions; 21.5% were treated only once. In all,
9.2% of the patients underwent the TACE procedure more
than 10 (total range: 1–25) times (Table S3, Supplemental
digital content 1, http://links.lww.com/EJGH/A236). The
most frequent reason for cessation of TACE therapy
was untreatable tumor progression (29%) (Table S4,
Supplemental digital content 1, http://links.lww.com/
EJGH/A236).
Survival analysis and prognostic factors
By the end of follow-up, 155/186 (83.3%) of all patients
had died. Median follow-up duration for patients alive
was 34.9 (range: 3.5–80.6) months, and median follow-up
for all patients as estimated by the reverse Kaplan–Meier
method was 53.7 months. Overall median survival was
16.9 (95% CI: 14.4–20.6) months (Fig. 1a). The 1-, 3-,
and 5-year OS rates were 65.1, 22.5, and 9.7%,
respectively.
Univariate analysis
A total of 17 parameters showed a significant influence on
survival in univariate analysis: tumor-related (Table 1) –
tumor extension (P=0.026), number of tumor nodes
(P=0.002), up-to-seven criteria (P=0.016), distant
metastasis (P=0.035), and tumor burden of at least 50%
(P=0.011); clinical (Table 1) – ascites (P= 0.031) and age
(P=0.025); laboratory (Table S5, Supplemental digital
content 1, http://links.lww.com/EJGH/A236) – α-feto
protein (AFP) (P<0.0001), bilirubin (P=0.003), alkaline
phosphatase (P<0.0001), glutamic oxaloacetic transaminase
(P<0.0001), glutamic pyruvic transaminase (P=0.006),
Quick (P=0.0117), albumin (P=0.028), C-reactive protein
(CRP) (P<0.0001), creatinine (P=0.0154), and lactate
dehydrogenase (P=0.005).
Table 1. Baseline parameter, univariate analysis, Munich-TACE cohort
Parameters n (%)
Median survival (95% CI)
(months) P value
Sex 0.632
Female 36 (19.4) 15.2 (12.7–28.3)
Male 150 (80.6) 16.9 (14.3–21.0)
Age (median: 65.5) (years) 0.025
<60 46 (24.7) 13.8 (7.2–16.9)
60–65 47 (25.3) 16.5 (11.5–25.3)
66–71 47 (25.3) 26.8 (18.3–35.0)




Alcohol 85 (45.7) 20.3 (15.2–22.5)
HCV 36 (19.4) 14.6 (10.8–27.6)
Cryptogenic 23 (12.4) 16.4 (9.4–26.8)
Liver cirrhosis 0.125
No 30 (16.1) 28.3 (12.7–35.2)
Yes 156 (83.9) 15.8 (13.8–18.3)
Ascites 0.031
No 134 (72.0) 20.1 (15.8–25.3)
Moderate 36 (19.4) 10.6 (6.9–20.3)
Severe 16 (8.6) 5.8 (2.7–21.7)
Hepatic encephalopathy 0.071
No 153 (82.3) 18.6 (15.6–22.5)
Moderate 33 (17.7) 7.3 (5.2–13.7)
ECOG 0.261
0 117 (62.8) 18.6 (14.6–25.3)
1 65 (35.0) 15.2 (9.2–20.3)
2 4 (2.2) 15.1 (2.7–26.0)
Portal hypertension 0.107
No 65 (36.1) 23.8 (14.4–29.7)
Yes 115 (63.9) 16.4 (14.3–20.3)
Portal vein thrombosis 0.695
No 161 (86.6) 17.1 (14.6–21.3)
Yes 25 (13.4) 14.3 (6.0–30.1)
Number of tumor nodes 0.002
1 52 (27.9) 23.8 (14.4–32.5)
2 36 (19.4) 22.9 (12.8–35.0)
3 24 (12.9) 18.2 (3.9–25.6)
>3 74 (39.8) 14.3 (11.5–16.8)
Tumor extensiona (cm) 0.026
Singular <2 5 (2.7) 14.6 (2.2–)
Three nod ≤3, one
nod≤5
22 (11.8) 34.6 (10.8–85.5)
Large or multilocular 115 (61.8) 17.1 (14.4–21.0)
Vascular involvement, M1 44 (23.7) 13.8 (6.9–17.4)
Tumor burden 0.011
≤50% 170 (91.3) 17.1 (14.6–21.3)
>50% 16 (8.7) 13.7 (3.4–22.5)
Up-to-seven criteriab 0.016
In 56 (30.3) 28.0 (16.0–34.6)
Out 129 (69.7) 15.6 (13.7–18.6)
Tumor size >7 cm 0.947
No 127 (69.0) 17.1 (14.4–21.3)
Yes 57 (31.0) 16.7 (11.4–23.8)
Lymph nodes ≥1 cm 0.678
No 132 (70.9) 16.1 (14.2–20.6)
Yes 54 (29.1) 20.3 (13.7–24.0)
Vascular invasion 0.908
No 158 (84.9) 16.9 (14.4–21.3)
Yes 28 (15.1) 15.2 (6.9–28.3)
Distant metastasis 0.035
No 169 (90.8) 18.1 (15.2–21.7)
Yes 17 (9.2) 11.6 (3.9–16.5)
HCV, hepatitis C virus; CI, confidence interval; EOCG, Eastern Cooperative
Oncology Group; nod, nodule.
aModified from BCLC (Forner et al. [3]). bSum of the size of the largest tumor and
the total number of tumors.
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Staging systems
Stratification of patients and estimated median survival
time according to the staging systems are depicted in
Table 2. Stratification according to BCLC revealed that
109 of the 186 patients received TACE outside of stage B,
especially stage C was represented strongly (41.9%). Apart
from TNM (P=0.066), all staging systems possessed a
significant association with prognosis. Figures 1 and 2
show the Kaplan–Meier survival analysis stratified
according to the staging systems. In the next step, the
discriminatory quality of the staging systems was
examined. All of the strata in GETCH and STATE
characterized distinct survival groups. All other scores
had at least two adjacent stages lacking distinct survival
times. Stages B and C of BCLC did not have a distinct
survival (P= 0.95) (Table 2). Thirty-five BCLC-C
patients were assigned to this more advanced stage and
not to stage B solely on the basis of their ECOG 1 status
(Table S6, Supplemental digital content 1, http://links.
lww.com/EJGH/A236). When including these patients in
BCLC-B, there was a slight tendency toward separation
of the BCLC-B and BCLC-C survival times (Fig. S1,
Supplemental digital content 1, http://links.lww.com/
EJGH/A236); however, this remained nonsignificant
(P= 0.657).
Multivariate analysis
In the final prognostic model, five laboratory parameters
and one radiological parameter [tumor extension;
P=0.008; hazard ratio (HR): 2.077] remained significant
predictors of survival (Table S7, Supplemental digital
content 1, http://links.lww.com/EJGH/A236). Of the
laboratory parameters, one was tumor related (AFP:
P<0.0001; HR: 3.618), two were liver function related
(Quick: P=0.0124; HR: 1.617; bilirubin: P=0.0001; HR:
3.144), and two were neither directly tumor related nor
liver related (creatinine: P= 0.0207; HR: 1.657; CRP:
P<0.0001; HR: 3.349). The nearly congruent course of
the Kaplan–Meier and Cox regressions curves in each of
the three stages of the prognostic model based on these
parameters (Fig. S2, Supplemental digital content 1, http://
links.lww.com/EJGH/A236), as well as the high c-index of
0.736, demonstrated an excellent applicability on the
internal TACE collective (internal validation).
Construction of Munich-TACE
On the basis of the six parameters of the final model (Table
S7, Supplemental digital content 1, http://links.lww.com/
EJGH/A236), the M-TACE score was constructed. Table 3
shows the allocation of score points subject to a patient’s
exact laboratory values and tumor extension, respectively.
Fig. 1. Overall survival internal transarterial chemoembolization (TACE) cohort (a); Kaplan–Meier survival curves for Child–Pugh (b), TNM (c), Okuda (d).
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Patients in the range of 0–9 points are allocated to stage I
(low mortality risk group); stage II (intermediate mortality
risk group) is defined by the range of 10–13; and stage III
patients (high mortality risk group) have 14–26 points. In
particular, high CRP (≥2.0 mg/dl), AFP (≥1000 ng/ml),
and bilirubin values (≥3.1 mg/dl) have a high impact on
mortality risk, each resulting in the allocation of 6 points.
Three points are given, whenever these parameters do not
reach the above-mentioned cutoff value, but still are in the
pathological range. An advanced tumor extension (cate-
gory B) is accounted for with 4 points, whereas deranged
values of creatinine and Quick have a comparatively low
weighting (2 points). Of note, substituting Quick with
international normalized ratio (INR) [similar HR of 1.617
(95% CI: 1.109–2.357) vs. 1.59 (1.053–2.279)] did not
result in changes of M-TACE stratification. When applied
Fig. 2. Kaplan1Meier survival curves for CLIP (a), BCLC (b), JIS (c), GETCH (d), HAP (e), STATE (f). BCLC, Barcelona-Clinic-Liver-Cancer; CLIP, Cancer-of-
the-Liver-Italian-Program; GETCH, Groupe-d’Etude-et-de-Traitement-du-Carcinome-Hepatocellulaire; HAP, Hepatoma-Arterial-embolization-Prognostic;
JIS, Japan Integrated Staging; STATE, Selection-for-Transarterial-Chemoembolisation-Treatment.
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to the 186 TACE patients, M-TACE yielded three
Kaplan–Meier survival curves with distinct survival (each
P< 0.0001) (Fig. 3a). Patients in stage I (n=55) had a
median survival of 35.2 (95% CI: 32.4–53.9) months,
stage II (n=70) patients of 16.9 (95% CI: 13.7–21)
months, and stage III patients (n= 61) had a low median
survival of 8.6 (95% CI: 5.9–11.6) months.
Table 2. Univariate analysis of the staging systems
Scores n (%)
Median survival months
(95% CI) P value
Child–Pugh 186 <0.0001
No cirrhosis 30 (16.1) 28.3 (12.7–35.2) –
A 86 (46.2) 21.0 (16.4–28.8) nc vs. A: 0.62
B 53 (28.5) 13.5 (8.8–15.6) A vs. B: 0.003
C 17 (9.1) 5.5 (3.0–9.2) B vs. C: 0.092
TNM 186 0.066
I 36 (19.4) 23.1 (11.2–41.3) –
II 69 (37.1) 20.3 (16.4–28.0) I vs. II: 0.255
III 62 (33.3) 14.4 (9.8–17.1) II vs. III: 0.101
IV 19 (10.2) 13.7 (4.9–25.6) III vs. IV: 0.875
Okuda 186 0.001
I 111 (59.7) 22.2 (16.8–27.6) –
II 68 (36.6) 10.8 (7.3–15.2) I vs. II: 0.0006
III 7 (3.8) 9.2 (1.3–21.7) II vs. III: 0.539
BCLC 186 0.001
A 12 (6.5) 42.0 (14.6–85.5) –
B 77 (41.4) 18.1 (14.4–24.2) A vs. B: 0.005
C 78 (41.9) 16.0 (13.7–21.3) B vs. C: 0.945
D 19 (10.2) 5.9 (3.4–10.8) C vs. D: 0.029
CLIP 186 <0.0001
0 17 (9.1) 47.5 (28.3–63.8) –
1 73 (39.2) 22.3 (18.1–32.2) 0 vs. 1: 0.016
2 60 (32.3) 14.3 (11.6–15.6) 1 vs. 2: 0.001
3 24 (12.9) 10.1 (6.1–18.3) 2 vs. 3: 0.406
≥4 12 (6.5) 3.4 (2.3–5.2) 3 vs. ≥4: <0.0001
JIS 186 <0.0001
0 2 (1.0) – (42.0–) –
1 24 (12.9) 24.5 (11.2–41.3) 0 vs. 1: 0.299
2 85 (45.7) 20.1 (16.8–26.8) 1 vs. 2: 0.189
3 54 (29.0) 13.7 (10.5–20.3) 2 vs. 3: 0.357
4 18 (9.7) 5.7 (3.6–9.2) 3 vs. 4: 0.004
5 3 (1.6) 3.4 (2.7–3.8) 4 vs. 5: 0.011
GETCH 186 <0.0001
Low risk 62 (33.3) 32.5 (21.3–41.3) –
Intermediate risk 118 (63.4) 14.4 (11.6–16.8) L vs. I: <0.0001
High risk 6 (3.2) 3.4 (1.3–15.2) I vs. H: <0.0001
HAP 186 <0.0001
A 30 (35.0) 35.0 (21.3–41.3) –
B 66 (22.2) 22.2 (16.0–30.1) A vs. B: 0.208
C 64 (12.8) 12.8 (7.9–16.5) B vs. C: 0.002
D 26 (9.0) 9.0 (5.2–11.6) C vs. D: 0.063
STATE 186 <0.0001
≥18 140 (75.3) 20.3 (16.4–25.3)
<18 46 (24.7) 9.0 (5.5–15.2)
M-TACE 186 <0.0001
I 55 (29.6) 35.2 (32.4–53.9) –
II 70 (37.6) 16.9 (13.7–21.0) I vs. II: <0.0001
III 61 (32.8) 8.6 (5.9–11.6) II vs. III: <0.0001
M-TACE (external) 71 <0.0001
I 38 (53.5) 68.1 (30.9–68.1)
II 22 (31.0) 12.9 (9.3–16.9) I vs. II: <0.0001




A+no cirrhosis 45 (63.4) 40.0 (16.9–68.1)
B 24 (33.8) 9.4 (5.0–26.8) (B+C)
C 2 (2.8)
CLIP (external) 71 <0.0001
0 6 (8.5) – (30.9–) –
1 34 (47.9) 68.1 (13.5–68.1) 0 vs. 1: 0.206
2 21 (29.6) 16.9 (9.3–40.0) 1 vs. 2: 0.118
3 6 (8.5) 6.4 (1.9–) 2 vs. 3: 0.136
≥4 4 (5.6) 4.0 (1.5–13.2) 3 vs. ≥4: 0.397
Staging systems were applied to the internal cohort. In addition, M-TACE, CLIP,
and Child–Pugh were applied to the external cohort as well.
BCLC, Barcelona-Clinic-Liver-Cancer; CI, confidence interval; CLIP, Cancer-of-the-
Liver-Italian-Program; HAP, Hepatoma-Arterial-embolization-Prognostic; JIS, Japan
Integrated Staging; M-TACE, Munich-TACE; nc, no cirrhosis; STATE, Selection-for-
Transarterial-Chemoembolisation-Treatment; TACE, transarterial chemoembolization.
Table 3. M-TACE score
Points
0 2 3 4 6
AFP (ng/ml) <35 – 35–999 – ≥1000
Bilirubin (mg/dl) <1.1 – 1.1–3.0 – ≥3.1
CRP (mg/dl) <0.5 – 0.5–1.9 – ≥2
Tumor extensiona Category A – – Category B –
Creatinine (mg/dl) <1.3 ≥1.3 – – –
Quick (%) ≥75 <75 – – –
Stage I (low mortality risk): 0–9 points
Stage II (intermediate mortality risk): 10–13 points
Stage III (high mortality risk): 14–26 points
AFP, α-feto protein; CRP, C-reactive protein; INR, international normalized ratio.
aTumor extension category B: positive if one of the following criteria is met: large
(one nodule >5 cm) or multilocular (exceeding the limits of three nodules ≤3 cm)
or vascular involvement or M1. Otherwise category A. For further external use, the
parameter Quick can be replaced by INR (>1.2 vs. ≤1.2).
Fig. 3. M-TACE applied to internal TACE cohort. Stage I versus II:
P<0.0001; stage II versus III: P<0.0001 (a). M-TACE applied to external
TACE cohort (external validation); stage I versus II: P<0.0001; stage II
versus III: P=0.015 (b). M-TACE, Munich-TACE; TACE, transarterial che-
moembolization.
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Ranking
To distinguish the staging systems’ prognostic ability, AIC
and c-index were calculated. Table 4 depicts the ranking
results on the basis of these two tests. Regarding the
established staging systems, CLIP (AIC: 1305; c-index:
0.677) was identified as the best score, followed by the
TACE-specific HAP score (AIC: 1322; c-index: 0.654). Of
note, BCLC had inferior prognostic qualities (AIC: 1345;
c-index: 0.597). M-TACE outperformed all staging sys-
tems in terms of AIC (1247) and c-index (0.71). As a sign
of consistency, the top three scores took the same rank in
either of the tests, as did the bottom-ranked TNM.
External validation
The major characteristics of the external TACE patient
population (n= 71) are shown in Tables S8 and S9
(Supplemental digital content 1, http://links.lww.com/
EJGH/A236). TACE components used were mitomycin C,
lipiodol, and degradable starch microspheres. Age and sex
distribution was similar as was the ECOG status.
However, viral hepatitis (43.7%) and not alcohol (28.2%)
was the leading etiological factor. There was a clear ten-
dency toward less advanced tumors: only 63.4% (vs.
85.4%) had the higher tumor extension category B (large
or multilocular tumors, vascular infiltration, or distant
metastases). Only 22.5% had a tumor size of more than
7 cm compared with 31% in the internal cohort.
Moreover, less Child C patients were documented (2.8 vs.
9.2%). As opposed to the internal cohort, the majority of
patients were assigned to M-TACE stage I (53.3 vs.
29.6%). Consequentially, the median OS was longer (22.9
vs. 16.9 months). M-TACE stages I, II, and III had a
median survival of 68.1, 12.9, and 5.6 months, respec-
tively (Fig. 3b and Table 2). The good discriminatory
ability of M-TACE was underlined by the significantly
different survival times between the three stages (stage I vs.
II, P< 0.0001; stage II vs. III, P= 0.015). As a whole,
M-TACE revealed a highly significant meaning for survival
(P<0.0001). CLIP, the established system with the best
performance in the internal cohort, and Child–Pugh were
tested in the external patient population for comparative
reasons. Although both scores showed an overall good
performance (P<0.0001 and P= 0.002, respectively),
their discriminatory ability was not as good as that of
M-TACE, with nonsignificant survival differences between
all CLIP stages and between Child B and C (Table 2).
Ranking according to c-index confirmed these results:
0.754 (M-TACE) versus 0.689 (CLIP) and 0.637
(Child–Pugh).
Discussion
Patient cohort and transarterial chemoembolization
characteristics
The study identified M-TACE as the superior prognostic
score for TACE patients when compared with all relevant
staging systems. The major advantage of the study was the
homogeneous treatment collective M-TACE was devel-
oped in, exclusively considering first-line conventional
TACE patients. Even the recently published TACE-specific
scores were developed in less homogeneous (and smaller)
cohorts, including different techniques [51% bland
embolization (HAP) and 43% DEB-TACE (STATE)] and
26% non-first-line TACE patients (STATE), respectively
[10,11]. Patient selection in the STATE study was on the
basis of BCLC, including only stage A and B patients
( + ECOG 1) and excluding 61 BCLC-C patients, although
the prognostic accurateness of BCLC in nonsurgical
patients has repeatedly been challenged [7,21] and our
data show that BCLC-B and BCLC-C TACE patients do
not show distinct survival. In terms of baseline parameters,
the main results of our study are comparable to those of
other western TACE studies [22]. OS was 16.9 months,
compared with 15.0 in the HAP score cohort and
14.7 months in the STATE cohort. The rather long OS in
our external cohort (22.9 months) could be explained by
the high percentage of patients with comparatively good
liver function and less advanced tumors. Another TACE
study from Japan reported a median OS of 34 months in
patients with even better liver function [23], an observa-
tion highlighting the impact of patient selection on survi-
val. The TACE patients of the external cohort
(2005–2012) were mainly treated in the era of Sorafenib,
offering an option for systemic treatment after TACE
failure [1]. Whether this factor contributed to the survival
difference compared with the internal cohort (1999–2011)
could not be assessed in this study.
The median number of TACE interventions in the
internal cohort was 3 (range: 1–25); these data are well in
line with other TACE studies, especially the one from
Hucke and colleagues (identical median of three TACE
interventions in both Austrian cohorts). The percentage of
patients receiving only a single TACE intervention was
21.5 in the current study, compared with 14 and 18% in
the Austrian cohorts [10]. These data reflect the general
recommendation to repeat TACE if possible, to achieve the
maximum benefit [22].
Prognostic parameters
Six independent prognostic parameters were identified:
AFP is known to correlate with tumor extent and has
frequently been acknowledged as a risk factor for TACE
patients [23]. The observation in our study that values
Table 4. Internal TACE cohort: ranking of seven established HCC
staging systems and three new TACE-specific scores according to
c-index and AIC
Ranks Score c-Index (95% CI) AIC (AIC rank)
1 M-TACEa 0.710 (0.673–0.748) 1276 (1)
2 CLIP 0.677 (0.628–0.725) 1305 (2)
3 HAPa 0.652 (0.612–0.693) 1323 (3)
4 CHILD 0.625 (0.577–0.673) 1338 (6)
5 JIS 0.624 (0.574–0.674) 1334 (5)
6 GETCH 0.616 (0.574–0.658) 1326 (4)
7 OKUDA 0.600 (0.558–0.642) 1341 (7)
8 BCLC 0.597 (0.548–0.645) 1345 (9)
9 STATEa 0.584 (0.545–0.623) 1341 (8)
10 TNM 0.564 (0.512–0.616) 1348 (10)
In cases of discrepancy between c-index and AIC, the c-index was favored.
AIC, Akaike Information Criterion; BCLC, Barcelona-Clinic-Liver-Cancer; CI, con-
fidence interval; CLIP, Cancer-of-the-Liver-Italian-Program; HAP, Hepatoma-
Arterial-embolization-Prognostic; HCC, hepatocellular carcinoma; JIS, Japan
Integrated Staging; M-TACE, Munich-TACE; STATE, Selection-for-Transarterial-
Chemoembolisation-Treatment; TACE, transarterial chemoembolization; TNM, tumor,
node and metastasis.
aTACE-specific scores.
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greater than or equal to 1000 ng/ml are especially asso-
ciated with a poor prognosis in TACE patients, is sup-
ported by earlier studies [24]. With a comparable HR, no
difference in M-TACE patient stratification was observed
when using INR or Quick, respectively. For future external
and prospective validation, the use of INR to avoid
interlaboratory variation is justified. Bilirubin is incorpo-
rated in many HCC staging systems [3,14,16], and studies
focusing on TACE confirmed its prognostic significance in
this subgroup [25]. A large study on prognostic factors in
nonsurgical HCC patients even found bilirubin to be the
most important prognostic factor. The authors concluded
that liver function is more important for prognosis than
tumor characteristics [26]; this is further supported by the
fact that in our study the unidimensional liver function
score Child–Pugh worked much better than did the uni-
dimensional tumor classification TNM. Nevertheless, all
multidimensional HCC staging systems consider some sort
of radiological tumor characteristics, and the inclusion of
the tumor extension criteria within M-TACE is in line with
this observation. Of the six significant factors, CRP and
creatinine stand out, because neither of them has been
incorporated in any of the established HCC staging sys-
tems. However, CRP appeared within the recently intro-
duced TACE-specific STATE score [10]. Creatinine,
although obviously not a liver parameter, has repeatedly
been linked to prognosis in end-stage liver disease patients
as documented by the MELD score for liver transplant
allocation. An elevated creatinine was associated with a
higher risk of TACE-related mortality and reduced OS
[25]. The observation that in total two liver function, two
tumor, and two other parameters comprise the M-TACE
score underlines the need for a multidimensional HCC
staging system owing to the complex interplay of the
malignant tumor with a dysfunctional organ.
Performance of staging systems
It has been hypothesized that consequent utilization of
staging systems can actually improve survival in HCC
patients [1]. However, it has become increasingly clear that
because of the wide range of clinical presentations of
HCC, different staging systems should be applied to dif-
ferent subgroups [9]. TNM, which lacks any parameter
reflecting a patients liver function, is endorsed for surgical
patients [9] and its parameters in part rely on precise
pathological results; TNMs’ inferior performance in a
cohort of nonsurgical patients therefore comes as no sur-
prise. CLIP was identified as the established staging system
with the best performance. This confirms the results of an
earlier TACE study, which identified CLIP as the staging
system with the best AIC [7]. The HAP score authors
ranked their score highest compared with all other tested
scores, but constrictively stated an ‘at least as good per-
formance as CLIP’ [11]; thus a new staging system pro-
posed for TACE patients at least has to prove its superior
performance against the ‘benchmark’ score CLIP.
Lately, two TACE-specific pretherapeutic staging sys-
tems have been published [10,11]. Both the HAP and
STATE score are well designed and easy to use. The only
prognostic factor shared by all three relevant TACE scores
(HAP, STATE, and M-TACE) is tumor extension,
although characterized by different criteria: whereas
M-TACE includes number and size of tumor nodes, vas-
cular involvement, and extrahepatic spread, HAP con-
siders a maximum diameter of more than 7 cm and STATE
a tumor exceeding the ‘up-to-seven criteria’ [10]. In addi-
tion, overlapping criteria in two of the three scores are as
follows: bilirubin [>1mg/dl (HAP) vs. > 1 and >3mg/dl
(M-TACE)], AFP [> 400 ng/ml (HAP) vs. 35–999 and
≥ 1000 ng/ml (M-TACE)], CRP [>1mg/dl (STATE)
and 0.5–1.9 and ≥2mg/dl (M-TACE)], and albumin (HAP
and STATE). Although an ideal staging system should be
as simple as possible, the higher number of prognostic
factors in M-TACE and the finely graduation of some of its
parameters could be an explanation for its superior prog-
nostic performance.
European Association for the Study of the Liver and
American Association for the Study of Liver Diseases
endorse the Barcelona classification [4,5]. BCLC selectively
recommends TACE for stage B patients [3]. In contrast,
HCC patients outside of stage B do receive TACE therapy
in clinical practice [1,6,27]; in fact, TACE is the most
frequent first-line treatment in Europe, North America,
and China across all BCLC stages [28]. This observation
was underlined by the results of our retrospective study.
Here, less than half of the examined patients were in stage
B at the time of first TACE treatment. The two largest
subgroups BCLC-B (n=77) and BCLC-C patients (n= 78)
did not show distinct survival (P=0.945). Another study
suggested that a subset of BCLC-C patients (HAP stages A
or B) may benefit from TACE [29]. In addition, an ECOG
of more than 0 automatically excludes patients from
BCLC-B and therefore from TACE treatment, although a
recent study indicated that ECOG 1 could be included in
BCLC-B [30] and our own data show that ECOG 0 versus
1 is not a prognostic factor in TACE patients (P=0.261).
However, even after inclusion of ECOG 1 patients in the
BCLC-B stage, survival times of BCLC-B and BCLC-C
patients in our TACE cohort did not separate significantly
(P=0.657). In the light of these results, the allocation to
TACE through the BCLC treatment algorithm should be
reassessed. Prognostic parameters, partly not included in
BCLC, determine the prognosis of TACE patients.
Clinical implications
It is reassuring to find that M-TACE worked even better in
the external than in the internal population (c-index: 0.754
vs. 0.710), although the external cohort showed different
patient characteristics. Further study including a pro-
spective validation is needed before a routine use of
M-TACE for TACE prognosis in patient and study man-
agement can be endorsed. For a meaningful staging
system, linkage to treatment indication is mandatory [3].
A possible M-TACE treatment algorithm is outlined
in Fig. 4. Patients in stage II are ‘typical’ TACE candidates,
whereas patients in stage I can receive TACE with pre-
sumably longer survival time. Patients in stage III, how-
ever, are characterized by a poor prognosis. Therefore,
alternate, noninvasive palliative treatment strategies such
as sorafenib or best supportive care should be favored.
Although this treatment algorithm can be useful for con-
ceptualizing treatment options, a too dogmatic approach
holds the danger of withholding patients from more
aggressive therapy. Therefore, M-TACE should not be a
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substitute but rather a supportive tool for individual multi-
disciplinary treatment decisions. The putative advantage of
the two other TACE scores HAP and STATE is the lower
score complexity. However, a ‘bedside calculation of the
score’ as indicated by Hucke et al. [10] is not of great clinical
importance, because every HCC treatment should be deci-
ded upon in a tumor board of an experienced HCC center
[1] and our score still is easy enough to be applied in this
setting: M-TACE demands the decision of an experienced
radiologist whether the tumor is large, multifocal, or shows
vascular or extrahepatic involvement, with one positive fac-
tor being sufficient to assign the four score points; the
remaining M-TACE points are solely dependent on objective
laboratory parameters. The M-TACE score is focussed on
pretherapeutic prognosis estimation, it does not provide
advice to the question whether to perform sequential TACE
sessions. Scores considering post-first-TACE prognostic fac-
tors do exist [31] but follow a different approach and are not
useful for the process of deciding whether to TACE a HCC
patient at all. Therefore, clinicians need two different TACE
scores as sketched by the START strategy [10]. On the basis
of the performance of M-TACE in the present study, it can
be regarded as a promising staging system for the initial
c-TACE treatment decision in treatment-naive HCC patients.
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